Rehovot (Israel), November 4, 2009

The patent, entitled “Cosmetic and Pharmaceutical Foam,” covers Foamix’s emulsion-based foams and their use for bacterial, fungal and viral infections, inflammatory conditions, and many other disorders.

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled “Cosmetic and Pharmaceutical Foam.” The patent covers Foamix’s vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company’s Emollient Foam technology platform. Claimed uses include the treatment of bacterial, fungal and viral infections, inflammatory conditions, and many other dermatological and mucosal disorders, including vaginal disorders.

“The continuing demand for our platform foam technology and our products is international. By incorporating drugs in foam vehicles, we can achieve advanced foam products with properties that afford higher patient compliance, improved convenience, and better efficacy. Additionally, formulating active ingredients in Foamix foam vehicles facilitates effective product life-cycle management, backed by Foamix’s extensive patent portfolio,” said Dr. Dov Tamarkin, the Company's CEO.

“We actively file for patent protection for our platform technologies and range of products in development. A key component of our business strategy is to create and build on a strong patent portfolio to offer protection to a growing range of foam technologies and products, which we can license out to our clients. Having an Emollient-Foam patent approved in Mexico is one more degree of protection that we can provide to our licensees and add to our granted “Cosmetic and Pharmaceutical Foam” patents in New Zealand and South Africa," explained David Schuz, Foamix’s Senior Vice President of Intellectual Property and Head of Strategic Research.

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has seventeen issued patents worldwide covering its foam and OilGel technology platforms and in excess of 150 pending applications of which more than a third are filed in the United States. The Company employs a leading U.S. patent counsel (WilmerHale LLC).

About Foamix:

Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a plurality of projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix’s psoriasis foam product licensed to Dr. Reddy's Laboratories, Inc and marketed by Promius Pharma under the trade mark Scytera™ has been launched in the United States in early 2009.

For additional information please visit www.foamix.co.il